Systems and methods using a solvent for the removal of lipids from fluids

a technology of fluid removal and solvent, applied in the direction of flow mixer, chemical/physical process, other medical devices, etc., can solve the problems of ischemia of the tissue supplied by the blood vessel, acute obstruction and ischemia of the distal blood vessel, and exposing fatty plaque deposits that may break away and embolize within the circulation, so as to reduce the amount of time needed

Inactive Publication Date: 2006-03-23
ELI LILLY & CO
View PDF99 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026] An advantage of this invention is that fluid can be processed in a continuous manner and returned to a patient without requiring withdrawal of an unacceptable level of blood from the patient. Furthermore, this invention may be used as a discontinuous or batch system for processing fluid, such as plasma from a blood bank.
[0027] Another advantage of this invention is that the concentration of lipids in a fluid or lipids in lipid-containing organisms, or both, may be reduced in a fluid in a time efficient manner.
[0028] Yet another advantage of this invention is that portions of these systems that contact a fluid during operation are capable of being produced as disposable members, which reduces the amount of time needed to prepare a system for use by another patient.

Problems solved by technology

Over time, these atherosclerotic lesions may ulcerate, exposing fatty plaque deposits that may break away and embolize within the circulation.
Atherosclerotic lesions obstruct the lumens of the affected blood vessels and often reduce the blood flow within the blood vessels, which may result in ischemia of the tissue supplied by the blood vessel.
Embolization of atherosclerotic plaques may produce acute obstruction and ischemia in distal blood vessels.
Such ischemia, whether prolonged or acute, may result in a heart attack or stroke from which the patient may or may not recover.
Similar ischemia in an artery supplying an extremity may result in gangrene requiring amputation of the extremity.
However, use of a patient's diet as a primary mode of therapy requires a major effort on the part of patients, physicians, nutritionists, dietitians, and other health care professionals and thus undesirably taxes the resources of health professionals.
Another negative aspect of this therapy is that its success does not rest exclusively on diet.
Thus, therapy based only on correcting flaws within a patient's diet is not always successful.
Hypolipidemic drugs have had varying degrees of success in reducing blood lipid; however, none of the hypolipidemic drugs successfully treats all types of hyperlipidemia.
While some hypolipidemic drugs have been fairly successful, the medical community has not found any conclusive evidence that hypolipidemic drugs cause regression of atherosclerosis.
In addition, all hypolipidemic drugs have undesirable side effects.
As a result of the lack of success of dietary control, drug therapy and other therapies, atherosclerosis remains a major cause of death in many parts of the world.
While having been fairly successful, this treatment has resulted in complications due to introduction of foreign proteins and transmission of infectious diseases.
Further, plasma exchange undesirably removes many plasma proteins, such as very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).
Therefore, removal of HDL from plasma is not desirable.
Furthermore, LDL removal may be counterproductive because low LDL levels in a patient's blood may result in increased cellular cholesterol synthesis.
Thus, removal of LDL from a patient's blood may have negative side effects.
While lipid apheresis has the potential to overcome the shortcomings of dietary control, drug therapy and other apheresis techniques, existing apparatuses and methods for lipid apheresis do not provide a sufficiently rapid and safe process.
Unfortunately, existing lipid apheresis systems suffer from a number of disadvantages that limit their ability to be used in clinical applications, such as in doctors' offices and other medical facilities.
One disadvantage is the explosive nature of the solvents used to delipidate this plasma.
Thus, it would be advantageous to limit this exposure; however, this hazard is clearly present for the duration of the delipidation process, which usually runs for several hours.
Another disadvantage is the difficulty in removing a sufficient amount of solvents from the delipidated plasma in order for the delipidated plasma to be safely returned to a patient.
In addition, patients are subjected to an increased chance of prolonged exposure to solvents in a continuous system.
Furthermore, current techniques do not provide for sequential multi-washes because the volume of blood necessary for continuous processing using conventional equipment requires removal of an amount of blood that would harm the patient.
In other words, conventional equipment does not allow for automated continuous removal, processing and return of plasma to a patient in a manner that does not negatively impact total blood volume of the patient.
While the long-term toxicity of various extraction solvents is not known, especially when present in the bloodstream, clinicians know that some solvents may cross the blood-brain barrier.
Furthermore, external contact with solvents is known to cause clinical symptoms, such as irritation of mucous membranes, contact dermatitis, headaches, dizziness and drowsiness.
Therefore, conventional equipment for lipid apheresis is not adequate to conduct continuous processing of a patient's blood.
While the medical community has struggled to develop cures for hyperlipidemia and arteriosclerosis, it has likewise struggled in its battle against infectious diseases.
Infectious diseases are a major cause of suffering and death throughout the world.
Infectious disease of varied etiology affects billions of animals and humans each year and inflicts an enormous economic burden on society.
Numerous bacteria and viruses that affect animals and humans cause extreme suffering, morbidity and mortality.
While some forms of hepatitis may be treated with drugs, other forms have not been successfully treated in the past.
Such a focus has created major difficulty with existing treatments, especially with regard to HIV.
Specifically, the high mutation rate of the HIV virus often renders treatments ineffective shortly after application.
Finally, many common therapies for HIV infection involve several undesirable side effects and require patients to ingest numerous pills daily.
Unfortunately, many individuals are afflicted with multiple infections caused by more than one infectious agent, such as HIV, hepatitis and tuberculosis.
Such individuals require even more aggressive and expensive drugs to counteract disease progression.
Such drugs may cause numerous side effects as well as multi-drug resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systems and methods using a solvent for the removal of lipids from fluids
  • Systems and methods using a solvent for the removal of lipids from fluids
  • Systems and methods using a solvent for the removal of lipids from fluids

Examples

Experimental program
Comparison scheme
Effect test

first example

(a) First Example

[0124] In accordance with the process described above and the embodiments, shown in FIGS. 2 and 3, human plasma was delipidated in an apparatus according to this invention by first introducing the plasma into a homogenizer with an equal volume of di-isopropyl ether (DIPE). The homogenizer used was a T25 UltraTurrax with a 25 mm diameter rotor head available from IKA Works of Germany. The homogenizer generated droplets having a diameter of about 5 um. The fluids were homogenized for about 6 minutes while the dispersion head rotated at about 24,000 rpm. The delipidated plasma containing residual delipidating solvent was then introduced into a solvent extraction device that resembled the subsystem shown in FIG. 17. The fluid was circulated through the hollow fibers of the HFCs at a flow rate of about 750 ml / min. Each HFC had a hold-up volume of about 50 ml and an area of about 4,800 cm2. Air was circulated through the shell of the HFC to extract the residual delipidati...

second example

(b) Second Example

[0126] This same apparatus was used to delipidate human plasma through numerous experiments. The speed of the homogenizer was varied between about 13,050 rpm and about 27,050 rpm and ran for between about one minute and about four minutes. This equated to an addition of 0.05 watts of energy per ml of solvent and fluid while running the homogenizer at about 13,050 rpm, and an addition of about 0.91 watts of energy per ml of solvent and fluid while running the homogenizer at about 27,050 rpm. The amounts of materials removed are the percentages of total concentrations of materials removed from initial concentrations of the materials in the fluid after running the homogenizer for about four minutes. The amount of cholesterol removed from the human plasma ranged between about 62.2% to about 91.5% for homogenizer speeds varied between about 13,050 rpm and about 27,050 rpm, respectively. The amount of triglycerides removed from the human plasma ranged between about 35.6%...

third example

(c) Third Example

[0128] Using a vortexer, as shown in FIGS. 7-9, human plasma was delipidated numerous times under various conditions. The amount of cholesterol, triglycerides, lipoprotein, phospholipids, apolipoprotein A1 and apolipoprotein B removed after adding 0.1 watts of energy per ml of fluid and solvent was about 30% after 10 minutes of running the vortexer, about 60% after 20 minutes, and about 90% after 30 minutes.

[0129] The percentages of constituents removed from the fluid differ when 1.0 watt of energy per milliliter of fluid and solvent was added using the vortexer. Specifically, the percentage of cholesterol removed from the fluid after one minute was about 67.3%, after two minutes was about 80.8%, after about 3 minutes was about 88.7%, after about 4 minutes was about 91.5%, and after about 8 minutes was about 95%. The percentage of triglycerides removed from the fluid after about one minute was about 53.1%, after about two minutes was about 64.6%, after about three ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Systems and methods for removing lipids from a fluid, such as plasma, or from lipid-containing organisms. A fluid is combined with at least one extraction solvent, which causes the lipids to separate from the fluid or from lipid-containing organisms. The separated lipids are removed from the fluid. The extraction solvent is removed from the fluid or at least reduced to an acceptable concentration enabling the delipidated fluid to be administered to a patient without the patient experiencing undesirable consequences. Once the fluid has been processed, the fluid may be administered to a patient who donated the fluid, to a different patient, or stored for later use.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 60 / 301,159, filed Jun. 25, 2001, and U.S. Provisional Patent Application No. 60 / 346,094, filed Jan. 2, 2002, which are incorporated by reference herein.FIELD OF THE INVENTION [0002] This invention relates to systems, apparatuses and methods for the removal of lipids from fluids, especially plasma, or from lipid-containing organisms, or both, using a single extraction solvent. After being processed, the fluid may be administered to an animal or human for therapeutic use such as treatment of arteriosclerosis and atherosclerotic vascular diseases, removal of fat within an animal or human, and reduction of infectivity of lipid-containing organisms. BACKGROUND OF THE INVENTION Hyperlipidemia and Arteriosclerosis [0003] Cardiovascular, cerebrovascular, and peripheral vascular diseases are responsible for a significant number of deaths annually in many industrializ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): B01D63/02
CPCA61M1/34A61M1/3486A61M1/3496A61M2202/0456A61M2202/08A61M2202/203A61M2202/206B01D11/0415B01D11/0457B01D61/246B01D61/36B01D63/02B01D2317/02B01F5/0646B01F5/0647B01F5/10B01F7/1635B01F9/02B01F11/0014B01F11/0283B01F2009/0063A61M1/3472A61M1/3482B01D11/0492B01D11/0488A61M1/3403A61M2205/3306A61M2205/3368B01F25/4331B01F25/433B01F25/50B01F27/8111B01F29/4033B01F29/60B01F31/22B01F31/87
Inventor BOMBERGER, DAVID C.CHAVEZ, BRYANGARCIA, PABLO E.HEGWER, ERICLOW, THOMAS P.MALHOTRA, RIPUDAMANSHIMON, JEFFREY J.
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products